AVAlisa Varentsova

Alisa Varentsova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alisa Varentsova has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Serum biochemical profile in case of cardiorenal syndrome in cats with hypertrophic cardiomyopathy

    by Yu. A. Vatnikov, E. D. Sotnikova, V. I. Kuznetsov, A. A. Razumova, I. V. Shchurov, O. A. Petrukhina, A. A. Rudenko

    Veterinary specialists have lately observed comorbidity of heart and kidney diseases known as cardiorenal syndrome. Cardiorenal syndrome is typically defined as dysfunction of a primarily intact kidney under the influence of a complex of pathogenetic damaging factors that arise against the background of an underlying cardiac disease. The purpose of the work is to study the biochemical profile of blood serum in cats with cardiorenal syndrome arising against the background of hypertrophic cardiomyopathy. The studies were carried out on 24 physiologically healthy (control) cats, 24 diseased cats with uncomplicated forms of pathology (first group) and 25 cats with hypertrophic cardiomyopathy complicated by cardiorenal syndrome (second group). It was shown that cardiorenal syndrome may occur as a complication of hypertrophic cardiomyopathy in animals. Biochemical tests in animals with feline cardiorenal syndrome verified cytolysis of cardiomyocytes (increased serum activity of lactate dehydrogenase by 2.69 times, creatine phosphokinase by 2.02 times, increased serum concentration of cardiac troponin by 5.20 times as compared to healthy animals), azotemia (increased concentration in serum creatinine by 2.72 times, urea by 2.94 times, symmetric dimethylarginine by 2.60 times and cystatin C by 1.90 times as compared to healthy animals), enhanced ketogenesis, systemic inflammatory process (increased serum concentration of C-reactive protein by 1.55 times as compared to healthy animals), hypercholesterolemia, oxidative stress (decrease in serum activity of superoxide dismutase by 1.63 times, catalase by 4.67 times and glutathione peroxidase by 1.71 times, increase in the concentration of malondialdehyde by 1.79 times, ceruloplasmin by 2.50 times and diene conjugates by 1.85 times as compared to healthy animals), electrolyte imbalance in the form of hyperkalemia, hyponatremia, hyperphosphatemia and hypomagnesemia. Biochemical indicators such as serum concentrations of creatinine, troponin I, cystatin C, symmetric dimethylarginine and C-reactive protein can be considered reliable diagnostic markers for the presence of cardiorenal syndrome.


  • Results of Laboratory Control of Brucellosis and Leptospirosis of Animals in Russia

    by Gulnara Nurlygayanova, Vasily Belousov, Alisa Varentsova, Andrey Sharypov

  • STUDY OF THE BIOCIDAL ACTIVITY OF THE DISINFECTANT «ULTRADON» AGAINST LISTERIA MONOCYTOGENES, ENTEROCOCCUS FAECALIS, SALMONELLA ENTERITIDIS

    by Russian Federation «Central Scientific And Methodological Veterinary Laboratory» Moscow, A.A. Kremleva, Yu.A. Skomorina, A.A. Varentsova, V.I. Belousov

    The article presents the results of tests of the disinfectant "Ultradon" against microorganisms of the genera Salmonella, Listeria and Enterococcus. Various materials were used as a test object: tiles, plastic, glass, stainless steel, rubber products. Laboratory experiments to determine the effectiveness of Ultradon solutions in the disinfection of test surfaces contaminated with various test microorganisms showed that the disinfectant effect of the agent largely depended on the type of material of the treated surfaces and the type of test microorganisms. The results of the tests found that the "Ultraman" has antimicrobial activity against test cultures of gram-negative (Salmonella enteritidis) and gram-positive (Enterococcus faecalis) microorganisms at concentrations (the drug) is not less than 1% at an exposure of at least 10 min; to test the culture of Listeria monocytogenes at concentrations of 1% (by drug) exposure for at least 30 min; not less than 1.5% (drug) exposure at least 15 minutes; not less than 2% (by product) at an exposure of at least 10 min.